Abstract:DNA methylation is a vital epigenetic change that regulates gene transcription and helps to keep the genome stable. The deregulation hallmark of human cancer is often defined by aberrant DNA methylation which is critical for tumor formation and controls the expression of several tumor-associated genes. In various cancers, methylation changes such as tumor suppressor gene hypermethylation and oncogene hypomethylation are critical in tumor occurrences, especially in breast cancer. Detecting DNA methylation-driven genes and understanding the molecular features of such genes could thus help to enhance our understanding of pathogenesis and molecular mechanisms of breast cancer, facilitating the development of precision medicine and drug discovery. In the present study, we retrospectively analyzed over one thousand breast cancer patients and established a robust prognostic signature based on DNA methylation-driven genes. Then, we calculated immune cells abundance in each patient and lower immune activity existed in high-risk patients. The expression of leukocyte antigen (HLA) family genes and immune checkpoints genes were consistent with the above results. In addition, more mutated genes were observed in the high-risk group. Furthermore, a in silico screening of druggable targets and compounds from CTRP and PRISM databases was performed, resulting in the identification of five target genes (HMMR, CCNB1, CDC25C, AURKA, and CENPE) and five agents (oligomycin A, panobinostat, (+)-JQ1, voxtalisib, and arcyriaflavin A), which might have therapeutic potential in treating high-risk breast cancer patients. Further in vitro evaluation confirmed that (+)-JQ1 had the best cancer cell selectivity and exerted its anti-breast cancer activity through CENPE. In conclusion, our study provided new insights into personalized prognostication and may inspire the integration of risk stratification and precision therapy.

Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy

Targeting Non-histone Methylation in Gastrointestinal Cancers: From biology to clinic

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

RNA methylation and breast cancer: insights into m6A, m7G and m5C

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Crosstalk between Methylation and ncRNAs in Breast Cancer: Therapeutic and Diagnostic Implications

The Mechanism of DNA Methylation and miRNA in Breast Cancer

Protein arginine methyltransferases: promising targets for cancer therapy

Identification of a DNA Methylation-Driven Genes-Based Prognostic Model and Drug Targets in Breast Cancer: In silico Screening of Therapeutic Compounds and in vitro Characterization

Dysregulation of arginine methylation in tumorigenesis

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy

Methylomics and cancer: the current state of methylation profiling and marker development for clinical care

Methylation Modification, Alternative Splicing, and Noncoding RNA Play a Role in Cancer Metastasis Through Epigenetic Regulation

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug

Lysine Methylation of Transcription Factors in Cancer

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges

N6-Methyladenosine methylation modification in breast cancer: current insights